相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects Results of a Prospective, Randomized, Crossover Study
Jose Luis Ferreiro et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2011)
Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies
D. J. Angiolillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction
Ricardo Fontes-Carvalho et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Clopidogrel with or without Omeprazole in Coronary Disease
NEW ENGLAND JOURNAL OF MEDICINE (2011)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
CIRCULATION (2010)
Comparison Between the Effect of Omeprazole and Rabeprazole on the Antiplatelet Action of Clopidogrel
Suksiri Siriswangvat et al.
CIRCULATION JOURNAL (2010)
Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction Results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study
Young-Hoon Jeong et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2010)
Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel
David S. Small et al.
CLINICAL PHARMACOKINETICS (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Neena S. Abraham et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel
H. M. Judge et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Clopidogrel with or without Omeprazole in Coronary Artery Disease.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response
Ankie M. Harmsze et al.
THROMBOSIS AND HAEMOSTASIS (2010)
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents
Peter Wenaweser et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction
Young-Hoon Jeong et al.
THROMBOSIS RESEARCH (2010)
Concomitant Use of Clopidogrel and Proton Pump Inhibitors or Cimetidine After Acute Myocardial Infarction Would Increase the Risk of Re-Infarction
Sophie Sheng-Wen Wang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease
Jeffrey S. Berger et al.
CIRCULATION (2009)
Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies
Silvio Caccia et al.
DRUG SAFETY (2009)
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel
Nihar R. Desai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue et al.
LANCET (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacology of emerging novel platelet inhibitors
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
Jolanta M. Siller-Matula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease
Eli I. Lev et al.
AMERICAN HEART JOURNAL (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Continuation of proton pump inhibitors from hospital to community
Kenneth Grant et al.
PHARMACY WORLD & SCIENCE (2006)
Drug therapy - Drug metabolism and variability among patients in drug response
GR Wilkinson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction
WC Lau et al.
CIRCULATION (2003)
Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood
RF Storey et al.
PLATELETS (2001)
Identification of the platelet ADP receptor targeted by antithrombotic drugs
G Hollopeter et al.
NATURE (2001)
分享论文
